Welcome to our dedicated page for Centessa Pharmaceuticals plc American Depositary Shares news (Ticker: $CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Centessa Pharmaceuticals plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Centessa Pharmaceuticals plc American Depositary Shares's position in the market.
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced the pricing of a $100 million public offering of 10,810,810 American Depositary Shares at $9.25 per ADS. The company expects to receive approximately $100 million in gross proceeds from this offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) has announced a proposed public offering of $100 million of American Depositary Shares (ADSs), with the intention to grant underwriters an option to purchase additional shares. The offering is subject to market conditions and led by Goldman Sachs and Leerink Partners. The ADSs are offered under a registration statement on Form S-3 filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) has received FDA clearance for the Investigational New Drug application to start a Phase 1 clinical trial of ORX750 for narcolepsy treatment. ORX750, an orexin receptor 2 agonist, targets orexin neuron loss in narcolepsy types 1 and 2, idiopathic hypersomnia, and other sleep-wake disorders. The study will assess safety, tolerability, and pharmacokinetics of ORX750 in healthy adults, with proof-of-concept data expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
Rhea-AI Summary
Centessa Pharmaceuticals plc (CNTA) reports recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. The company is focused on the registrational studies of SerpinPC for hemophilia B, advancing its orexin agonist program, and evaluating its LockBody technology platform. Recent data shows promising results for SerpinPC, with a 96% reduction in bleeding rates, and no thrombosis observed. The company plans to share clinical proof-of-concept data for ORX750 in 2024. Financially, Centessa has $256.5 million in cash, research & development expenses of $29.7 million, general & administrative expenses of $12.3 million, and a net loss of $36.8 million for the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (CNTA) to participate in TD Cowen's 44th Annual Health Care Conference in Boston, MA. A fireside chat scheduled for March 5th. Live audio webcast and archived recording available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announces the presentation of additional 52-week data from the ongoing Phase 2a study of SerpinPC for hemophilia treatment at EAHAD Congress. SerpinPC shows promise as a novel inhibitor of activated protein C, with positive results reinforcing its potential as a convenient subcutaneous treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.13%
Tags
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced its participation in upcoming investor conferences, including Guggenheim’s 6th Annual Biotechnology Conference and Leerink Partners Global Biopharma Conference 2024. The live webcasts and archived recordings will be available on the company's investor relations section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Saurabh Saha MD PhD, CEO, to present on January 10, 2024, at 4:30 PM PST. The event will be available for live audio webcast and archived recording on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) presented additional data from the third year of the Phase 2a study of SerpinPC for the treatment of hemophilia at the American Society of Hematology (ASH) Annual Meeting. The data showed a 96% reduction in the median all-bleed annualized bleeding rate (ABR) from the prospective baseline, reinforcing the favorable safety and tolerability profile of SerpinPC. No thromboembolic events or treatment-related sustained elevations of D-dimer were observed during the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA): Ongoing studies for hemophilia B treatment, new data at ASH Annual Meeting, preclinical data on narcolepsy treatment presented at World Sleep Congress, financial results and business highlights for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
Centessa Pharmaceuticals plc American Depositary Shares
Nasdaq:CNTA
CNTA Rankings
CNTA Stock Data
1.07B
43.89M
2.33%
84.02%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
ALTRINCHAM, CHESHIRE
About CNTA
centessa pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. the company applies an asset-centric r&d model at scale to advance a portfolio of highly validated programs led by industry leading teams. each program is developed by a centessa subsidiary and supported by a centralized infrastructure and the centessa management team. the company is headquartered in cambridge, mass.